



Getting Started Guide

To get a patient started on Mycapssa® follow 2 steps outlined in this guide



Becky, Mycapssa patient

**Visit chiesitotalcare.com
or call 1-833-346-2277
We're ready to help!**

INDICATION AND IMPORTANT SAFETY INFORMATION

INDICATION AND USAGE

Mycapssa (octreotide) delayed-release capsules, for oral use, is a somatostatin analog indicated for long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide.

Please see additional Important Safety Information throughout and accompanying full Prescribing Information.





If you have questions, visit chiesitotalcare.com or call 1-833-346-2277 – we're ready to help!

INDICATION AND IMPORTANT SAFETY INFORMATION

INDICATION AND USAGE

Mycapssa (octreotide) delayed-release capsules, for oral use, is a somatostatin analog indicated for long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide.

CONTRAINDICATIONS

Hypersensitivity to octreotide or any of the components of Mycapssa. Anaphylactoid reactions, including anaphylactic shock, have been reported in patients receiving octreotide.

WARNINGS AND PRECAUTIONS

Mycapssa can cause problems with the gallbladder. Monitor patients periodically. Discontinue if complications of cholelithiasis are suspected.

Blood sugar, thyroid levels, and vitamin B₁₂ levels should be monitored and treated accordingly.

Bradycardia, arrhythmia, or conduction abnormalities may occur. Treatment with drugs that have bradycardia effects may need to be adjusted.

New onset of steatorrhea, stool discoloration, loose stools, abdominal bloating, and weight loss may occur with Mycapssa and other somatostatin analogs. If new occurrence or worsening of these symptoms are reported, evaluate for potential pancreatic exocrine insufficiency and manage accordingly.

ADVERSE REACTIONS

The most common adverse reactions (incidence >10%) are nausea, diarrhea, headache, arthralgia, asthenia, hyperhidrosis, peripheral swelling, blood glucose increased, vomiting, abdominal discomfort, dyspepsia, sinusitis, and osteoarthritis.

DRUG INTERACTIONS

The following drugs require monitoring and possible dose adjustment when used with Mycapssa: cyclosporine, insulin, antidiabetic drugs, calcium channel blockers, beta blockers, lisinopril, digoxin, bromocriptine, and drugs mainly metabolized by CYP3A4. Counsel women taking an oral contraceptive to use an alternative non-hormonal method of contraception or a back-up method when taking Mycapssa.

Patients taking proton pump inhibitors, H₂-receptor antagonists, or antacids concomitantly with Mycapssa may require increased dosages of Mycapssa.

PREGNANCY

Advise premenopausal females of the potential for an unintended pregnancy.

Please report adverse events to Chiesi Farmaceutici S.p.A. at 1-888-661-9260 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see additional Important Safety Information and accompanying full Prescribing Information.

For more information, visit mycapssa.com.

Chiesi Total CareSM Program offered through PANTHERx Rare Pharmacy.

©Chiesi USA, Inc. 2025. All rights reserved.

Mycapssa[®] is a registered trademark owned by the Chiesi Group.

PANTHERx Rare PharmacySM is a registered service mark of PANTHERx Specialty LLC.

Chiesi Total CareSM is a service mark owned by Chiesi Farmaceutici S.p.A.

PP-MC-0002 V4.0

